Incyte Corp Financials
Incyte Corp (INCY) reported $5.1B in revenue for fiscal year 2025, up 21.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Incyte runs a very high-gross-margin business where profitability is shaped mainly by research spending swings, not by weak core economics.
Across the last two years, gross margin was92.6% and92.8% , so the recovery was not driven by materially better unit economics. Below gross profit, R&D intensity eased and operating margin jumped from1.5% to29.5% , making the prior year's slump look more like a spending reset than a broken revenue engine.
Cash conversion looked much cleaner in the latest year: operating cash flow reached
The balance sheet ended in a cash-heavy posture, with
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Incyte Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Incyte Corp has an operating margin of 29.5%, meaning the company retains $29 of operating profit per $100 of revenue. This strong profitability earns a score of 75/100, reflecting efficient cost management and pricing power. This is up from 1.5% the prior year.
Incyte Corp's revenue surged 21.2% year-over-year to $5.1B, reflecting rapid business expansion. This strong growth earns a score of 79/100.
Incyte Corp carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.32, Incyte Corp holds $3.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 80/100.
Not available for Incyte Corp, and counted as zero in the overall score.
Incyte Corp earns a strong 24.9% return on equity (ROE), meaning it generates $25 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 73/100. This is up from 0.9% the prior year.
Incyte Corp scores 10.79, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($25.9B) relative to total liabilities ($1.8B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Incyte Corp passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Incyte Corp generates $1.10 in operating cash flow ($1.4B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Incyte Corp earns $623.91 in operating income for every $1 of interest expense ($1.5B vs $2.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Incyte Corp generated $5.1B in revenue in fiscal year 2025. This represents an increase of 21.2% from the prior year.
Incyte Corp's EBITDA was $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 967.7% from the prior year.
Incyte Corp reported $1.3B in net income in fiscal year 2025. This represents an increase of 3846.9% from the prior year.
Incyte Corp earned $6.41 per diluted share (EPS) in fiscal year 2025. This represents an increase of 4173.3% from the prior year.
Cash & Balance Sheet
Incyte Corp held $3.1B in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Incyte Corp's gross margin was 92.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.
Incyte Corp's operating margin was 29.5% in fiscal year 2025, reflecting core business profitability. This is up 28.0 percentage points from the prior year.
Incyte Corp's net profit margin was 25.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 24.3 percentage points from the prior year.
Incyte Corp's ROE was 24.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 23.9 percentage points from the prior year.
Capital Allocation
Incyte Corp invested $2.1B in research and development in fiscal year 2025. This represents a decrease of 21.4% from the prior year.
Incyte Corp repurchased no shares in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
INCY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4B | $5.1B+21.2% | $4.2B+14.8% | $3.7B+8.9% | $3.4B+13.7% | $3.0B+12.0% | $2.7B+23.5% | $2.2B+14.7% | $1.9B+22.5% | $1.5B+38.9% | $1.1B+46.7% | $753.8M+47.4% | $511.5M+44.1% | $354.9M+19.5% | $297.1M+214.5% | $94.5M |
| Cost of Revenue | $403.5M | $372.1M+19.2% | $312.1M+22.4% | $255.0M+23.2% | $207.0M+37.1% | $151.0M+15.0% | $131.3M+14.9% | $114.2M+21.4% | $94.1M+18.4% | $79.5M+36.6% | $58.2M+115.7% | $27.0M+797.9% | $3.0M+376.8% | $630K+301.3% | $157K | N/A |
| Gross Profit | $5.0B | $4.8B+21.4% | $3.9B+14.2% | $3.4B+7.9% | $3.2B+12.4% | $2.8B+11.8% | $2.5B+24.0% | $2.0B+14.4% | $1.8B+22.7% | $1.5B+39.1% | $1.0B+44.1% | $726.8M+42.9% | $508.5M+43.5% | $354.3M+19.3% | $296.9M | N/A |
| R&D Expenses | $2.1B | $2.1B-21.4% | $2.6B+60.2% | $1.6B+2.6% | $1.6B+8.8% | $1.5B-34.2% | $2.2B+92.0% | $1.2B-3.7% | $1.2B-9.7% | $1.3B+127.9% | $581.9M+21.3% | $479.5M+38.0% | $347.5M+33.4% | $260.4M+23.8% | $210.4M+17.7% | $178.7M |
| SG&A Expenses | $1.4B | $1.4B+10.8% | $1.2B+7.5% | $1.2B+15.3% | $1.0B+35.5% | $739.6M+43.1% | $516.9M+10.3% | $468.7M+7.9% | $434.4M+18.6% | $366.3M+20.8% | $303.3M+54.2% | $196.6M+18.6% | $165.8M+50.7% | $110.0M+28.8% | $85.4M+46.6% | $58.2M |
| Operating Income | $1.6B | $1.5B+2368.6% | $61.4M-90.1% | $620.5M+7.1% | $579.4M-1.1% | $585.8M+322.2% | -$263.7M-165.6% | $402.0M+211.1% | $129.2M+153.1% | -$243.4M-267.9% | $145.0M+186.3% | $50.7M+1154.4% | -$4.8M+70.2% | -$16.1M-1502.6% | $1.1M+100.8% | -$143.2M |
| Interest Expense | $2.3M | $2.4M+6.5% | $2.3M-10.6% | $2.6M-4.3% | $2.7M+39.7% | $1.9M-12.2% | $2.2M+17.2% | $1.9M+20.2% | $1.5M-77.6% | $6.9M-82.2% | $38.7M-15.0% | $45.6M-2.6% | $46.8M+21.2% | $38.7M-16.1% | $46.1M+5.1% | $43.8M |
| Income Tax | $342.1M | $377.8M+33.0% | $284.0M+20.0% | $236.6M+25.6% | $188.5M+149.8% | -$378.1M-695.7% | $63.5M+59.2% | $39.9M+581.3% | $5.9M+587.1% | $852K-73.2% | $3.2M+210.4% | $1.0M+1653.0% | -$66K-122.1% | $299K+71.8% | $174K | N/A |
| Net Income | $1.4B | $1.3B+3846.9% | $32.6M-94.5% | $597.6M+75.4% | $340.7M-64.1% | $948.6M+420.8% | -$295.7M-166.2% | $446.9M+308.2% | $109.5M+135.0% | -$313.1M-400.5% | $104.2M+1495.8% | $6.5M+113.5% | -$48.5M+41.7% | -$83.1M-87.6% | -$44.3M+76.2% | -$186.5M |
| EPS (Diluted) | — | $6.41+4173.3% | $0.15-94.3% | $2.65+74.3% | $1.52-64.4% | $4.27+414.0% | -$1.36-166.3% | $2.05+302.0% | $0.51+133.3% | -$1.53-383.3% | $0.54+1700.0% | $0.03+110.3% | -$0.29+48.2% | -$0.56 | N/A | N/A |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
INCY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.0B+27.8% | $5.4B-19.7% | $6.8B+16.1% | $5.8B+18.4% | $4.9B+38.5% | $3.6B+3.9% | $3.4B+29.5% | $2.6B+14.9% | $2.3B+40.5% | $1.6B+62.6% | $1.0B+26.5% | $796.5M+26.5% | $629.6M+90.5% | $330.4M+0.4% | $329.0M |
| Current Assets | $5.0B+55.1% | $3.2B-30.3% | $4.6B+13.5% | $4.1B+31.2% | $3.1B+32.2% | $2.4B-4.9% | $2.5B+35.4% | $1.8B+21.8% | $1.5B+51.4% | $994.2M+18.0% | $842.4M+24.0% | $679.6M+22.3% | $555.8M+79.6% | $309.5M-0.4% | $310.8M |
| Cash & Equivalents | $3.1B+83.5% | $1.7B-47.5% | $3.2B+8.9% | $3.0B+43.5% | $2.1B+36.0% | $1.5B-17.4% | $1.8B+57.4% | $1.2B+29.4% | $899.5M+37.9% | $652.3M+25.1% | $521.4M+15.3% | $452.3M-4.1% | $471.4M+110.4% | $224.1M-18.0% | $273.2M |
| Inventory | $101.1M+71.7% | $58.9M-6.5% | $63.0M+50.0% | $42.0M+50.5% | $27.9M+69.9% | $16.4M+44.1% | $11.4M+63.6% | $7.0M+7.5% | $6.5M+57.9% | $4.1M+130.3% | $1.8M+398.0% | $358K-11.8% | $406K+46.0% | $278K | N/A |
| Accounts Receivable | $1.0B+20.1% | $853.2M+14.7% | $743.6M+15.3% | $644.9M+4.6% | $616.3M+27.9% | $482.0M+56.1% | $308.8M+0.4% | $307.6M+15.5% | $266.3M+79.0% | $148.8M+30.0% | $114.5M+97.6% | $57.9M+63.8% | $35.4M-50.1% | $71.0M+1006.0% | $6.4M |
| Goodwill | $133.0M-14.5% | $155.6M0.0% | $155.6M0.0% | $155.6M0.0% | $155.6M0.0% | $155.6M0.0% | $155.6M0.0% | $155.6M0.0% | $155.6M0.0% | $155.6M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.8B-10.3% | $2.0B+25.4% | $1.6B+8.3% | $1.5B+26.4% | $1.2B+22.5% | $949.6M+14.6% | $828.3M+15.1% | $719.8M+7.1% | $672.0M-44.9% | $1.2B+45.8% | $836.3M-4.8% | $878.1M+6.7% | $822.7M+62.8% | $505.4M-9.1% | $556.0M |
| Current Liabilities | $1.5B-7.7% | $1.6B+32.4% | $1.2B+7.2% | $1.2B+35.4% | $854.3M+35.3% | $631.2M+23.0% | $513.3M+20.7% | $425.3M+13.3% | $375.4M+37.3% | $273.5M+62.8% | $168.0M-24.0% | $221.1M+104.6% | $108.0M-20.6% | $136.1M+0.3% | $135.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $26.8M-96.4% | $749.8M0.0% | $749.8M-10.8% | $840.9M-0.7% | $846.6M+106.5% | $410.0M+29.7% | $316.2M |
| Total Equity | $5.2B+49.9% | $3.4B-33.6% | $5.2B+18.8% | $4.4B+15.9% | $3.8B+44.4% | $2.6B+0.5% | $2.6B+34.9% | $1.9B+18.1% | $1.6B+288.7% | $419.5M+145.1% | $171.2M+309.7% | -$81.6M+57.7% | -$193.1M-10.4% | -$175.0M+23.0% | -$227.1M |
| Retained Earnings | $213.8M+119.9% | -$1.1B-768.9% | $160.4M+136.7% | -$437.2M+43.8% | -$777.9M+54.9% | -$1.7B-20.7% | -$1.4B+23.8% | -$1.9B+5.6% | -$2.0B-18.8% | -$1.7B+5.9% | -$1.8B+0.4% | -$1.8B-2.8% | -$1.7B-5.0% | -$1.7B-2.8% | -$1.6B |
INCY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.5B | $1.4B+321.5% | $335.3M-32.5% | $496.5M-48.8% | $969.9M+29.4% | $749.5M+701.5% | -$124.6M-117.5% | $710.7M+111.4% | $336.2M+461.6% | -$93.0M-130.5% | $304.8M+240.9% | $89.4M+240.5% | $26.3M+186.0% | $9.2M+109.7% | -$94.8M+41.4% | -$161.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $77.8M-57.0% | $181.0M-3.4% | $187.4M+140.0% | $78.1M+6.2% | $73.5M-33.8% | $111.0M-7.7% | $120.3M+362.6% | $26.0M-6.7% | $27.9M+553.3% | $4.3M+50.3% | $2.8M-25.3% | $3.8M |
| Free Cash Flow | N/A | N/A | N/A | N/A | $892.1M+56.9% | $568.5M+282.2% | -$312.0M-149.3% | $632.6M+140.8% | $262.7M+228.8% | -$204.0M-210.6% | $184.5M+191.0% | $63.4M+4013.9% | -$1.6M-133.0% | $4.9M+105.0% | -$97.7M+41.0% | -$165.5M |
| Investing Cash Flow | -$191.9M | -$102.6M-165.1% | $157.5M+175.8% | -$207.7M-164.4% | -$78.5M+62.2% | -$207.7M+22.8% | -$269.0M-207.6% | -$87.5M-1.2% | -$86.4M+75.3% | -$350.0M-50.5% | -$232.5M-121.4% | -$105.0M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $198.5M | $101.0M+105.0% | -$2.0B-9991.1% | -$20.0M-2423.0% | -$794K-112.9% | $6.2M-91.4% | $71.7M+56.9% | $45.7M+211.9% | $14.7M-97.9% | $690.2M+1446.8% | $44.6M-47.3% | $84.7M | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $0-100.0% | $2.0B | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
INCY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.8%+0.1pp | 92.6%-0.5pp | 93.1%-0.8pp | 93.9%-1.0pp | 94.9%-0.1pp | 95.1%+0.4pp | 94.7%-0.3pp | 95.0%+0.2pp | 94.8%+0.1pp | 94.7%-1.7pp | 96.4%-3.0pp | 99.4%-0.4pp | 99.8%-0.1pp | 100.0% | N/A |
| Operating Margin | 29.5%+28.0pp | 1.5%-15.3pp | 16.8%-0.3pp | 17.1%-2.6pp | 19.6%+29.5pp | -9.9%-28.5pp | 18.6%+11.8pp | 6.9%+22.7pp | -15.8%-28.9pp | 13.1%+6.4pp | 6.7%+7.7pp | -0.9%+3.6pp | -4.5%-4.9pp | 0.4% | -151.6% |
| Net Margin | 25.0%+24.3pp | 0.8%-15.4pp | 16.2%+6.1pp | 10.0%-21.7pp | 31.8%+42.9pp | -11.1%-31.8pp | 20.7%+14.9pp | 5.8%+26.2pp | -20.4%-29.8pp | 9.4%+8.6pp | 0.9%+10.3pp | -9.5%+14.0pp | -23.4%-8.5pp | -14.9% | -197.5% |
| Return on Equity | 24.9%+23.9pp | 0.9%-10.6pp | 11.5%+3.7pp | 7.8%-17.4pp | 25.2%+36.5pp | -11.3%-28.5pp | 17.2%+11.5pp | 5.7%+24.9pp | -19.2%-44.0pp | 24.9%+21.0pp | 3.8% | N/A | N/A | N/A | N/A |
| Return on Assets | 18.5%+17.9pp | 0.6%-8.2pp | 8.8%+3.0pp | 5.8%-13.4pp | 19.2%+27.5pp | -8.3%-21.3pp | 13.0%+8.9pp | 4.1%+17.7pp | -13.6%-20.0pp | 6.4%+5.7pp | 0.7%+6.7pp | -6.1%+7.1pp | -13.2%+0.2pp | -13.4%+43.3pp | -56.7% |
| Current Ratio | 3.32+1.3x | 1.97-1.8x | 3.75+0.2x | 3.54-0.1x | 3.65-0.1x | 3.74-1.1x | 4.83+0.5x | 4.31+0.3x | 4.01+0.4x | 3.63-1.4x | 5.01+1.9x | 3.07-2.1x | 5.14+2.9x | 2.270.0x | 2.29 |
| Debt-to-Equity | 0.35-0.2x | 0.58+0.3x | 0.310.0x | 0.340.0x | 0.31-0.1x | 0.360.0x | 0.32-0.1x | 0.37+0.4x | 0.02-1.8x | 1.79-2.6x | 4.38 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | 26.3%+7.2pp | 19.0%+30.7pp | -11.7%-41.0pp | 29.3%+15.3pp | 14.0%+27.2pp | -13.3%-30.0pp | 16.7%+8.3pp | 8.4%+8.7pp | -0.3%-1.7pp | 1.4%+34.3pp | -32.9% | -175.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Incyte Corp Ranks
Frequently Asked Questions
What is Incyte Corp's annual revenue?
Incyte Corp (INCY) reported $5.1B in total revenue for fiscal year 2025. This represents a 21.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Incyte Corp's revenue growing?
Incyte Corp (INCY) revenue grew by 21.2% year-over-year, from $4.2B to $5.1B in fiscal year 2025.
Is Incyte Corp profitable?
Yes, Incyte Corp (INCY) reported a net income of $1.3B in fiscal year 2025, with a net profit margin of 25.0%.
What is Incyte Corp's EBITDA?
Incyte Corp (INCY) had EBITDA of $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Incyte Corp's gross margin?
Incyte Corp (INCY) had a gross margin of 92.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Incyte Corp's operating margin?
Incyte Corp (INCY) had an operating margin of 29.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Incyte Corp's net profit margin?
Incyte Corp (INCY) had a net profit margin of 25.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Incyte Corp's return on equity (ROE)?
Incyte Corp (INCY) has a return on equity of 24.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Incyte Corp's operating cash flow?
Incyte Corp (INCY) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Incyte Corp's total assets?
Incyte Corp (INCY) had $7.0B in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Incyte Corp spend on research and development?
Incyte Corp (INCY) invested $2.1B in research and development during fiscal year 2025.
What is Incyte Corp's current ratio?
Incyte Corp (INCY) had a current ratio of 3.32 as of fiscal year 2025, which is generally considered healthy.
What is Incyte Corp's debt-to-equity ratio?
Incyte Corp (INCY) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Incyte Corp's return on assets (ROA)?
Incyte Corp (INCY) had a return on assets of 18.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Incyte Corp's Altman Z-Score?
Incyte Corp (INCY) has an Altman Z-Score of 10.79, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Incyte Corp's Piotroski F-Score?
Incyte Corp (INCY) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Incyte Corp's earnings high quality?
Incyte Corp (INCY) has an earnings quality ratio of 1.10x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Incyte Corp cover its interest payments?
Incyte Corp (INCY) has an interest coverage ratio of 623.91x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Incyte Corp?
Incyte Corp (INCY) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.